Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0052 -0.0047 (-47.47%)

Streaming Delayed Price Updated: 10:27 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp. - Warrant

Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases ↗

May 23, 2023

Via Benzinga

Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels ↗

March 02, 2023

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in

Via Benzinga

Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events ↗

July 27, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals ↗

April 22, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date ↗

April 20, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study ↗

April 13, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program ↗

March 16, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.